(E)-2-(3-nitrostyryl)pyridine | 55532-26-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-2-(3-nitrostyryl)pyridine
• 英文别名: NSC 19637；2-(3-nitro-styryl)-pyridine；2-(3-nitro-trans-styryl)-pyridine；2-(3-Nitro-trans-styryl)-pyridin；2-(3-Nitro-styryl)-pyridin；(E)-2-[2-(3-nitrophenyl)vinyl]pyridine；2-(m-Nitrostyryl)pyridine；2-[(E)-2-(3-nitrophenyl)ethenyl]pyridine
• CAS: 55532-26-8
• 化学式: C₁₃H₁₀N₂O₂
• 分子量: 226.235
• InChiKey: NFTQPJVUAHNPTC-BQYQJAHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-2-(3-nitrostyryl)pyridine 在 磷化氢 、 氢碘酸 作用下， 生成 [3-(2-吡啶-2-基乙基)苯基]胺
  参考文献：
  名称：

  26. 2-甲基吡啶和芳香醛之间的反应

  摘要：

  DOI：

  10.1039/jr9330000077
• 作为产物：
  描述：

  碳酸甲丙酯 、 间硝基苯甲醛 在 三氟甲磺酰胺 、 bis(trifluoromethane)sulfonimide lithium 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以92%的产率得到(E)-2-(3-nitrostyryl)pyridine
  参考文献：
  名称：

  路易斯酸催化的 2-甲基氮杂芳烃与醛的苄基反应

  摘要：

  已经研究了路易斯酸催化的 2-甲基氮杂芳烃与醛的苄基反应。该反应得到一系列氮杂芳烃衍生物。首次通过LiNTf2促进的羟醛反应形成了具有常见取代基的2-(Pyridin-2-yl)乙醇。在 LiNTf2 与 H2NTf 协同作用下，合成了仅以 E 异构体形式存在的 2-烯基吡啶。在La(Pfb)3催化下，2-甲基喹啉与醛类在空气中反应，以高收率得到2-烯基喹啉。

  DOI：

  10.1002/ejoc.201400073

文献信息

• A novel <scp>d</scp>-glucosamine-derived pyridyl-triazole@palladium catalyst for solvent-free Mizoroki–Heck reactions and its application in the synthesis of Axitinib
  作者：Chao Shen、Hongyun Shen、Ming Yang、Chengcai Xia、Pengfei Zhang

  DOI：10.1039/c4gc01606h

  日期：——

  A novel d-glucosamine-derived pyridyl-triazole@palladium catalyst for solvent-free Mizoroki–Heck reactions and the synthesis of Axitinib is reported.

  报道了一种新型的D-氨基葡萄糖衍生的吡啶-三唑@钯催化剂，用于无溶剂水相的Mizoroki–Heck反应以及阿克替尼的合成。

• Compounds for use as therapeutic agents affecting p53 expression and/or activity
  申请人：Société Splicos

  公开号：EP2505198A1

  公开（公告）日：2012-10-03

  The present invention relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a -NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a -CONR7R8 group, a -SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a -(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a -(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use as an agent for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the invention.

  本发明涉及化合物(I)，其中R1和R2分别代表氢原子，(C1-C4)烷氧基，氟代(C1-C4)烷氧基，羟基，苄氧基，二(C1-C4)烷基氨基，吡啶基乙烯基，嘧啶基乙烯基，苯乙烯基，或-NHCO苯基；R3、R4和R5分别代表氢原子，(C1-C4)烷基，CONHR6基团，-CONR7R8基团，-SO2NHR6基团，或杂环烷基，可选择地被卤原子取代，-(CH2)nNR7R8基团或羟基(C1-C4)烷基；R6代表氢原子，-(CHR9)m(CH2)nNR7R8基团或(C1-C6)烷基，可选择地被羟基取代；或其药学上可接受的盐之一，用作预防、抑制或治疗患有该疾病的患者的药剂，所述疾病涉及到p53蛋白的失调。其中一些化合物是新的，也是本发明的一部分。
• Heterobicyclic derivatives
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：US20020107251A1

  公开（公告）日：2002-08-08

  Heterobicyclic derivatives of the formula: 1 wherein R 1 is aryl which may have suitable substituent(s), ar(lower)alkyl which may have suitable substituent(s), halo(lower)alkyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, heterocyclic group or heterocyclic(lower)alkyl which may have suitable substituent(s), R 2 is aryl which may have suitable substituent(s) or heterocyclic group, and R 3 is hydrogen, lower alkoxy or arylthio, and a pharmaceutically acceptable salt thereof which are useful as a medicament.

  公式为1的杂环双环衍生物，其中：R1是苯基，可以具有适当的取代基；芳基（较低）烷基，可以具有适当的取代基；卤代（较低）烷基；保护的羧基（较低）烷基；酰基（较低）烷基；杂环基或者可以具有适当的取代基的杂环（较低）烷基；R2是苯基，可以具有适当的取代基或者杂环基；R3是氢、较低烷氧基或者芳基硫醚。它们的药物可接受盐是有用的。
• COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY
  申请人：Scherrer Didier

  公开号：US20140206690A1

  公开（公告）日：2014-07-24

  The present invention relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C 1 -C 4 )alkoxy group, a fluoro(C 1 -C 4 )alkoxy group, a hydroxyl group, a benzyloxy group, a di(C 1 -C 4 )alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C 1 -C 4 )alkyl group, a CONHR6 group, a —CONR7R8 group, a —SO 2 NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH 2 ) n NR7R8 group or a hydroxy(C 1 -C 4 )alkyl group; R6 represents a hydrogen atom, a —(CHR9) m (CH 2 ) n NR7R8 group or a (C 1- C 6 )alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the invention.

  本发明涉及化合物(I)，其中R1和R2分别表示氢原子，(C1-C4)烷氧基，氟(C1-C4)烷氧基，羟基，苄氧基，二(C1-C4)烷基氨基，吡啶基乙烯基，嘧啶基乙烯基，苯乙烯基或—NHCO苯基；R3，R4和R5分别表示氢原子，(C1-C4)烷基，CONHR6基，—CONR7R8基，—SO2NHR6基或杂环基，所述杂环基可选地被卤原子，—(CH2)nNR7R8基或羟基(C1-C4)烷基取代；R6表示氢原子，—(CHR9)m(CH2)nNR7R8基或(C1-C6)烷基，可选地被羟基取代；或其药学上可接受的盐之一，用于预防，抑制或治疗患有p53失调的患者的疾病的方法。其中一些化合物是新的，也是本发明的一部分。
• Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0920867A1

  公开（公告）日：1999-06-09

  Heterobicyclic derivatives of formula (I) wherein R1 is aryl which may have suitable substituent(s), ar(lower)alkyl which may have suitable substituent(s), halo(lower)alkyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, heterocyclic group or heterocyclic(lower)alkyl which may have suitable substituent(s), R2 is aryl which may have suitable substituent(s) or heterocyclic group, and R3 is hydrogen, lower alkoxy or arylthio, and a pharmaceutically acceptable salt thereof which are useful as PDE IV and TNF inhibitors for the treatment of hepatitis in human beings and animals.

  式(I)的杂双环衍生物 其中 R1 是芳基，可具有合适的取代基；ar(低级)烷基，可具有合适的取代基；卤代(低级)烷基；受保护的羧基(低级)烷基；酰基(低级)烷基；杂环基团或杂环(低级)烷基，可具有合适的取代基、R2 是芳基（可有适当的取代基）或杂环基，R3 是氢、低级烷氧基或芳硫基，及其药学上可接受的盐，可作为 PDE IV 和 TNF 抑制剂用于治疗人类和动物的肝炎。